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ADIPOSE TISSUE FABP DEFICIENCY PROMOTES METABOLIC 
REPROGRAMMING AND POSITIVELY IMPACTS HEALTHSPAN 
 
ABSTRACT 
The adipose tissue lipid chaperones aP2 and mal1, also known as fatty acid 
binding proteins (FABPs), are significant molecules contributing to metabolic 
homeostasis, whereby their absence promotes physiological changes that improve 
systemic metabolism. Identification of palmitoleate as a lipokine generated in aP2-
mal1 deficiency—originating from adipose and directing the lipogenic program in 
liver, established a role for these chaperones in linking adipocyte and hepatic 
function. We have recently demonstrated a functional role for secreted aP2 in the 
activation of gluconeogenesis and hepatic glucose output, further designating this 
molecule as an adipocyte-derived regulatory factor that influences liver 
metabolism. Key molecules linking the metabolism of nutrients in energy 
generating pathways are the nucleotide cofactors NAD and NADH. Together, these 
molecules function to coordinate the maintenance of redox reactions during 
normal cellular metabolism and act as required substrates for enzymes such as 
sirtuins and poly ADP-ribose polymerases. Using global metabolite profiling, we 
show that combined deficiency of the adipose tissue lipid chaperones aP2 and 
mal1 leads to a hepatic nucleotide imbalance resulting from metabolic 
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reprogramming in liver. We demonstrate that this reprogramming of metabolite 
flux is accompanied by significant alterations in liver NAD metabolism and 
establish a role for aP2 in directing substrate utilization through inhibition of the 
rate-limiting enzyme for NAD synthesis, nicotinamide phosphoribosyltransferase. 
Several models for the proposed regulatory pathways that link nutrient 
metabolism to aging include mechanisms that are NAD dependent. Accordingly, 
we found that long-term FABP deficiency confers a strong resistance to aging 
related metabolic deterioration. Together, the findings presented in this thesis 
support a considerable role for FABPs in the regulation of NAD metabolism and 
healthspan. 
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METABOLISM AND AGING 
Growing old: healthspan vs. lifespan 
From the moment of creation and until death, all forms of life begin to 
experience the processes of aging. For some species, like the Californian 
Bristlecone Pine, these processes can occur over thousands of years. For humans 
and other higher order organisms, the chronology of aging is much shorter, 
marked by periods of physical and cognitive growth, occurring at time-points that 
follow the species norm.  In advanced adulthood, we begin to experience a decline 
in these physical and cognitive abilities, as our adaptive responses begin to loose 
efficacy and we become more susceptible to disease. For these reasons, our 
perception of age has progressed beyond one that is defined solely by time of 
existence, towards one that includes the condition of health. Undoubtedly, illness 
prevention has dramatically increased the average healthspan, however, our 
maximum lifespan remains limited to roughly 120 years (Ruiz-Torres and Beier, 
2005). Though there are many examples of maximal lifespan extension in yeast, 
Drosophila and mice, whether significant human lifespan extension can be 
achieved beyond the current limit remains to be answered. In fact, dietary 
restriction, an intervention shown to have lifespan extending effects in yeast, 
Drosophila, and mice, was demonstrated to have limited effects on lifespan in 
primates (Mattison et al., 2012). Nevertheless, we endeavor to understand what 
occurs over time, with respect to biological function, to ensure the inevitability of 
Chapter 1 Introduction           
 
	   3 
death. In doing so, we may be able to design interventions that add meaningful 
years to human healthspan. 
 
Metabolic and molecular links to aging 
The impact of reliable food sources, protection from environmental insults, 
medical advancement, and disease prevention has manifested as a three-fold 
increase in average human lifespan (National Center for Health Statistics, 2010). 
However, in today’s world, everyday life often includes daily routines marked by 
inactivity and nutritionally poor meals that are high in calories. Together, these 
lifestyle adjustments have led to a rise in obesity, negatively impacting healthspan 
and introducing metabolic syndrome (i.e., insulin resistance, type-2 diabetes, and 
atherosclerosis) as a new cause of disease related premature death (Katzmarzyk et 
al., 2005). Though it has been possible to identify behaviors and exposures that 
lead to metabolic disease, it is difficult to elucidate the underlying mechanisms. 
This is due to the immense heterogeneity in genetic composition and 
environmental exposures that contribute to the development of metabolic 
derangements. Despite this complexity, determining mechanism becomes a more 
tractable concept when assayed using genetically identical laboratory species. 
Thus far, such studies have revealed insulin and insulin like growth factor 1 
pathway modulation, mammalian target of rapamycin inhibition, and sirtuin 
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activation as putative interventions that oppose the decline in metabolic function 
and increase longevity (Cantó and Auwerx, 2011).  
The yeast sirtuin, Sir2p was first identified as a mediator of lifespan whereby 
mutations that inactivate Sir2p decreased survival, and introduction of a second 
copy of Sir2p conferred a 30% increase in replicative life span (Kaeberlein et al., 
1999). It was later determined that expression of Sir2p could be induced by shifting 
glucose availability from 2% to 0.5%, a method of dietary restriction in yeast. It is 
hypothesized that this form of DR increases Sir2p by initiating a metabolic switch 
from fermentation to respiration, creating more NAD from NADH which activates 
Sir2p, an NAD-dependent deacetylase (Imai et al., 2000; Lin et al., 2000).  
Though mammals possess a Sir2p orthologue (Sirtuin 1), the mechanism(s) 
of increased lifespan in mammals is complicated by the nature of an animal’s 
ability to respond to changes in energy availability through adaptive changes in 
glucose and fat utilization by metabolic tissues. This adaptive response involves 
suppression of glycolysis, enhanced liver gluconeogenesis and glucagon-
stimulated degradation of glycogen stores in order to maintain glucose levels 
during short-term caloric restriction. Insufficient availability of carbohydrates for 
prolonged periods of dietary restriction will stimulate lipolysis and mobilization of 
lipids from adipose tissue (Dhahbi et al., 2001). Thus, long-term dietary restriction 
results in lower steady state levels of glucose and insulin as well as an overall 
decrease in fat mass (Bertrand et al., 1980; Gabriely and Barzilai, 2001).  
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Dietary restriction in mammals is typically defined as a 25-60% reduction in 
total calories derived from carbohydrates, lipids, and proteins without invoking a 
state of malnutrition (Ricketts et al., 1985; Weindruch et al., 1986). Under this 
intervention, studies have shown life span extension to increase by as much as 
50% in dietary restricted rodents (Sohal and Weindruch, 1996) and to date, this 
phenomenon has held true across numerous species including yeast, spiders, flies, 
worms, and fish (Ingram et al., 1990). The emerging facts indicate that the benefits 
of longevity result from a delayed development of age related diseases, many of 
which have known causal links to metabolism such as type 2 diabetes, cancer and 
cardiovascular disease (Hursting et al., 2001; Lane et al., 1999; Manco and 
Mingrone, 2005). However, two dietary restriction studies spanning several 
decades revealed that rhesus monkeys subjected to this intervention displayed 
great extension of healthspan, but no increase in survival (Colman et. al. 2009 and 
Mattison et al., 2012). Despite much attention surrounding the life extending 
effects of DR, the regulatory factors mediating the relationship between a 
restrictive diet and postponement of mortality is currently unknown.  
 
 
Genetic models of extended lifespan  
Several genetic models for significantly increased lifespan have been reported over 
the years. Of note are mouse models harboring mutations in growth hormone 
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receptor (Ghrhrlit/lit) or growth hormone receptor binding protein (GHR/BP-/-), 
p66shc null mice, and IGF-I receptor heterozygous mice, all of which exhibit altered 
hormone secretion in the hypothalamic-pituitary axis (Bartke et al., 1998), and have 
been shown to affect many of the same physiological changes that occur during 
aging (reviewed in Liang et al., 2003). Dwarf mice, perhaps the most extensively 
characterized genetic models of longevity, consist of a collection of mutants that 
include both Snell and Ames mice, harboring point mutations in the pituitary 
specific transcription factor 1 gene (Pit1) and the Prop-1 gene upstream of Pit1, 
respectively. Each of these mutations result in poor secretion of growth hormone, 
thyroid-stimulating hormone, and prolactin, an outcome related to defective 
differentiation of their respective hormone secreting cells in the anterior pituitary. 
In addition to the expected growth phenotype as a consequence of lacking growth 
hormone, these mice also have a reduced metabolic rate and core body 
temperature, lower circulating levels of insulin, IGF-1 and glucose, and an overall 
increase in resistance to oxidative stress (Dominici et al., 2002). Expression profiling 
of liver tissue in Ames mice, which live up to 40-70% longer than their wild type 
counterparts (Brown-Borg et al., 1996) and dietary-restricted mice, revealed both 
separate and overlapping gene clusters that may represent clues towards the 
molecular basis underlying lifespan extension (Tsuchiya et al., 2004).  
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Adipose tissue in healthspan and lifespan 
Given the central role of adipose tissue in communicating the nutritional 
environment to peripheral tissues and in directing systemic energy flow, it is 
unsurprising that major energy shifts, such as one induced by dietary restriction, 
highly impact adipose tissue function. The opposite is also true, as dramatic 
alterations in adipose tissue function greatly influence systemic metabolic 
responses to nutritional inputs.  Decreased adiposity is associated with the 
activation of genes involved in carbohydrate, amino acid, lipid, and mitochondrial 
energy metabolism; each serving to expend energy. Adiponectin expression, 
which is reduced in obese humans and insulin resistant rodents (Hu et al., 1996), 
increases upon loss of fat mass  (Yang et al., 2001). Furthermore, surgical excision 
of white adipose tissue reverses hepatic insulin resistance that is induced by 
obesity and aging (Barzalai 1999 and Gabriely 2002).   
Taken together, a reduction in adiposity is followed by increased expression 
of genes involved in peripheral tissue insulin sensitization and systemic energy 
expenditure.  Yet, many ambiguities remain in determining the relationship 
between adipose tissue and the aging process. In fat-specific insulin receptor 
deficient mice, which have ~50% reduction white adipose tissue, similar caloric 
intake, and significantly longer lifespans than their wild type counterparts (Bluher 
et al., 2003), lifespan extension mediated by dietary restriction was shown to be 
inversely correlated with degree of fat loss. 
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PHYSIOLOGICAL ROLES OF THE ADIPOCYTE IN METABOLIC STABILITY AND 
PLASTICITY 
Conventional Functions 
Adipose tissue stores energy in the form of triglyceride (TG) filled lipid droplets, 
adjusting release of its contents based on the substrate requirements of peripheral 
tissues. Triglycerides are presented to the adipocyte in the form of dietary 
chylomicrons or liver derived lipoprotein particles and hydrolyzed through the 
action of lipoprotein lipase at the cell surface. When peripheral tissue substrate 
demands trigger hormonal signals that lead to adrenergic pathway activation, free 
fatty acids are liberated from lipid droplets via hydrolysis of TGs. In addition to the 
adipocyte, matrix fibroblasts, vascular endothelium, and a variety of immune cells 
all comprise the adipose tissue organ. Together, these cell types actively secrete an 
array lipids and proteins, termed adipokines, that function as key effectors of 
adaptive responses to metabolic alterations in peripheral tissues (Figure 1-1). For 
example, the earliest identified adipokines, leptin and adiponectin, influence 
energy homeostasis at multiple sites in the periphery. Leptin does so by binding to 
receptors in the hypothalamus to signal satiety and reduce food intake. 
Adiponectin receptors are more ubiquitously expressed, and their activation is 
associated with improved insulin sensitivity and increased fatty acid oxidation. In 
plasma, high leptin and low adiponectin are strongly correlated with degree of  
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Figure 1-1. Adipose tissue influence on systemic metabolism. 
 
 
 
 
 
 
 
 
 
Insulin secretion 
Gluconeogenesis Glucose uptake 
aP2-mal1-/- 
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adiposity and insulin resistance. This natural ebb and flow of adipokine secretion 
and systemic lipid flux occurs most prominently during feeding, fasting and 
exercise, necessitating a range of adipose tissue adaptive responses to maintain 
functional integrity of the adipocyte and proper communication with peripheral 
tissues.  
 
Adaptive responses 
The regulation of adipose tissue lipid content during fasting and increased 
energy expenditure is crucial for supporting the heightened demand for fuel 
substrates. For example, decreased insulin and increased glucagon stimulates 
adipose tissue lipolysis and subsequent release of free fatty acids to supply 
peripheral tissues, as an adaptive response to insufficient food intake. During 
exercise, the brain signals release of catecholamines, which stimulates lipolytic 
activity in the adipocyte and supplies working muscle with sufficient substrate 
levels needed to sustain the high levels of oxidation required for ATP generation. 
Interestingly, in lactating mice, strong evidence exists that the unfolded protein 
response transcription factor XBP-1 is required to maintain lipogenic gene 
expression and milk production by adipose derived mammary tissue, in response 
to prolactin (Gregor et al., 2013).  
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The ability to properly access these adaptive responses is affected by a 
variety of factors; among them are body fat percentage and composition of fatty 
acids in triglyceride reserves. (Sial et al., 1996, Fabbrini et al., 2012).  
 
 
Maladaptive responses 
Though adipose tissue is capable of expanding to accommodate excess energy, 
like all tissues, there is a limit to the functional capacity of this organ. Nutritional 
overload directly impacts adiposity, and induces both qualitative and quantitative 
changes in the adipocyte lipid droplet. Together these effects trigger anomalous 
metabolic behaviors, with major consequences on glucose and lipid homeostasis. 
First, the constant burden of overnutrition overwhelms the capabilities of the 
adipocyte and leads to ectopic lipid accumulation in circulation and the 
surrounding periphery. The presence of lipids in tissues that are not functionally 
equipped to deal with them can trigger dysfunction by exhausting the oxidative 
capacity of the organ, activating inflammatory mediators, altering organelle 
membrane composition and depositing toxic lipid species within cellular matrices 
(Navina et al, 2011). Secondly, endocrine function of many classical secretory 
organs is compromised in obesity (i.e. pancreatic insulin secretion), including 
adipose tissue adipokine release (Guilherme et al., 2004). These factors designate 
adipose tissue as a significant contributor to metabolic disease and, therefore, a 
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suitable site for identification of molecules that support the maintenance of 
systemic metabolism. 
 
ADIPOSE TISSUE FATTY ACID BINDING PROTEIN 4 
Expression and tissue distribution 
The fatty acid binding proteins (FABPs) are a small 14-15kDa family, comprised of 
10 members, with ubiquitous tissue distribution. While the degree of functional 
redundancy for all isoforms remains to be determined, it is known that some 
tissues strongly express one or multiple isoforms. For example, a single isoform, 
FABP5 can be found in the eye, whereas the ileum expresses high levels of FABPs 
1,2 and 6.  In other tissues like testis and adipose, expression is dominated by a 
single isoform, but also exhibits minor expression of one or more additional FABP 
family members (Yamamoto et al., 2009). The predominant adipose tissue isoform 
is FABP4 or adipocyte protein 2 (aP2). Expression of aP2 correlates with fat 
accretion, as levels rise during adipocyte differentiation as well as in the 
inflammatory and obese states (Hotamisligil, 2006). Also expressed in adipose 
tissue is FABP5, or epidermal fatty acid binding protein (mal1). Each of these 
isoforms are co-expressed in adipocytes and macrophages, however adipocyte aP2 
expression is roughly 10, 000-fold higher than macrophage aP2 expression (Shum 
et al., 2006).  
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Lipid chaperoning activity 
Adipocyte fatty acid binding protein, aP2, preferentially binds long chain fatty 
acids, and has a weaker affinity towards shorter chain fatty acids and some 
carboxylate derivatives (Furuhashi and Hotamisligil, 2008). The putative role of 
cytosolic fatty acid binding proteins, based on their ability to bind fatty acids and 
other lipids species, is to facilitate the intracellular trafficking of lipids to various 
organelles and cellular structures for their use as fuel substrates, membrane 
components, precursors for more complex lipids, or for storage in the lipid droplet. 
They may also function to present lipid ligands to proteins in the nuclear receptor 
family for downstream transcriptional activation. Adipocyte fatty acid binding 
protein aP2 has been linked to a variety of biological mechanisms, as mediators of 
both lipid trafficking and lipid-derived inflammatory signaling. For example, re-
localization of aP2 from the cytosol to nucleus has been observed upon exposure 
to fatty acid ligands known to function as peroxisome proliferator-activator 
receptor gamma (PPARγ) targets. indicating a potential role for aP2 in 
transcriptional activation by nuclear receptors (Nguan-Soon Tan et al., 2002). 
Furthermore, Erbay et al. (2009) demonstrated that macrophage aP2 was an 
important mediator of lipid-induced ER stress, and that macrophage aP2 deficiency 
was sufficient to protect against apoptosis and atherosclerosis caused by 
lipotoxicity.  
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Impact on systemic metabolism 
Mice deficient in adipose tissue fatty acid binding proteins aP2 and mal1 
demonstrate a surprising level of protection against obesity, and the development 
of atherosclerosis, insulin resistance, and type 2 diabetes when given a high-fat 
diet (Hotamisligil et al., 1996; Maeda et al., 2005). This is not surprising, given that 
adipose tissue is a crucial metabolic site, essential to the integration of signal 
inputs generated in the context of multiple dietary paradigms such as high-fat diet, 
short-term fasting, and long-term caloric restriction. Furthermore, adipose tissue 
fatty acid binding proteins facilitate the intracellular movement of lipids for their 
use in membrane formation, metabolic signaling and storage, all of which have the 
potential to impact the endocrine and systemic lipid trafficking functions of the 
adipocyte (Furuhashi and Hotamisligil, 2008).  
Work from our lab and others has demonstrated a profound impact of FABP 
deficiency on adipose tissue and plasma lipid composition (Baar, et al., 2004; 
Maeda et al., 2005; Cao et al., 2008), and a unique ability for FABP deficiency to 
promote secretion of a specific lipid species, palmitoleate (Cao et al, 2008). The 
absence of aP2 and mal1 stimulates adipose tissue de novo lipogenesis and 
synthesis of palmitoleate, a monounsaturated fatty acid with minor dietary orgins 
(Cao et al., 2008). This lipid was demonstrated as a novel adipokine having 
hormone like effects, as evidenced by its ability to suppress hepatic lipogenesis 
and increase insulin-mediated glucose uptake in muscle.  
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While these proteins have been thought to be mainly cytosolic, given that 
many of the striking phenotypes in adipose tissue FABP deficiency were observed 
in the periphery, it seemed reasonable that these proteins could also be secreted 
to function in an endocrine manner. As such, secreted aP2 was recently 
demonstrated to regulate hepatic gluconeogenesis through upregulation of 
gluconeogenic gene expression (Cao et al., 2013).  
Together, these data exposed two important features of the adipocyte. First, 
it revealed the capability of adipocytes to emit specific lipid signals that directly 
impact systemic metabolism. Secondly, it designated FABPs as molecules that link 
adipose tissue metabolism to peripheral tissue function.  
 
PREVIEW OF THESIS 
By developing the adipose tissue organ, we have evolved distinct mechanisms to 
both amass and re-distribute energy surplus. However, the efficient regulation of 
adipose tissue lipid content still requires the complex integration of 
environmental, hormonal, and nutritional inputs from the entire organ system.  
In the next 10 years, over half of the human population is expected to be obese. 
Thus, a fundamental understanding of the adipose tissue contribution to systemic 
metabolism is crucial to our ability to understand the functional limitations of this 
organ, and prevent the damaging effects of obesity on peripheral tissues. 
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Our approach is to examine the role of adipose tissue FABPs in the 
regulation of systemic metabolic circuitry through global metabolic profiling by 
using a mouse model deficient in the FABPs aP2 and mal1. Furthermore, given that 
these animals exhibit a remarkable protection against obesity and the associated 
co-morbidities, we aimed to use this genetic model to aid in our efforts in 
determining how protection from a decline in metabolic tissue function impacts 
survival and healthspan. 
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BACKGROUND 
Adipose tissue fulfills multiple roles in the orchestration of systemic 
substrate flux. Foremost, it acts as a rheostat for the circulating free fatty acid 
environment, balancing storage with lipolytic activity according to the needs of 
the organism. The endocrine function of adipocytes is becoming more widely 
appreciated, with the finding that they have the ability to secrete an ever-
expanding array of factors that influence metabolic programs in peripheral tissues 
(i.e. adiponectin, leptin, TNFα, Nampt /Visfatin, and palmitoleate) (MacDougald and 
Burant, 2007; Hotamisligil et al., 1993; Revollo et al., 2007; Cao et al., 2008). Thus, 
adipocyte function and peripheral tissue regulation are tightly linked. Since these 
links are deeply rooted in the functioning of biochemical pathways, and in the flux 
of nutrients on which these pathways rely, excess nutritional substrates present a 
challenge to the integrity of these metabolic networks.  
Unresolvable metabolic stress is a well-described feature of obesity, marked 
by dysregulation of major pathways used for routine management of nutritional 
energy. In liver, aberrant glucose and lipid metabolism present in obesity causes 
hepatic steatosis, increased glucose output, and increased lipoprotein particle 
formation. Together these contribute to the emergence of several obesity related 
co-morbidities, namely type-2 diabetes and cardiovascular disease (Malnick and 
Knobler, 2006), both contributing to and resulting from dysregulated glucose 
utilization and lipid metabolism in metabolic tissues. 
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Much work has been done to identify mechanisms that support the 
maintenance of metabolic networks disrupted in obesity (Khan et al., 2006; Van 
Gaal et al., 2006). We have chosen to approach this question by examining the role 
of adipose tissue fatty acid binding proteins (FABPs) in the regulation of metabolic 
circuitry. The FABPs aP2 and mal1 have the potential to regulate the localization 
and availability of fatty acids (Furuhashi et al., 2008), and are perhaps required, at 
least in part, for the incorporation of lipids into the metabolic network. As such, 
mice with combined genetic ablation of aP2 and mal1 are resistant to the 
deleterious effects of high fat diet and obesity (Maeda et al., 2005). A collection of 
studies has elucidated many of the phenotypic alterations that arise under adipose 
tissue FABP deficiency. Specifically, mice lacking aP2 and mal1 show a marked 
protection against hepatic lipid accumulation, the development of type-2 diabetes 
and insulin resistance when placed on a high-fat diet (Maeda et al., 2005) and also 
exhibit a remarkable resistance to cardiovascular disease (Makowski et al., 2001). 
This link between FABP deficiency and improved disease outcomes has also been 
established in humans, where subjects displaying an aP2 promoter region 
polymorphism resulting in lower adipose tissue aP2 levels present with a 
decreased risk for hypertriglyceridemia, type 2 diabetes and cardiovascular disease 
(Tuncman & Erbay et al., 2006). Despite this body of work, it is likely that additional 
mechanisms related to FABP action remain undetermined, given that these 
chaperones influence the availability of such a crucial substrate. Indeed, more 
recently our lab demonstrated that aP2 is a bona fide adipokine that regulates 
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hepatic glucose output by increasing gluconeogenic gene activity, a phenotype 
that is consistent with diminished hepatic glucose output in aP2-mal1 deficiency 
(Cao et al, 2008; Cao et al., 2013). Also prominent in aP2-mal1-/- animals are 
decreased liver lipogenesis and increased energy expenditure (Maeda et al., 2005).  
Key molecules linking the metabolism of nutrients in energy generating 
pathways are the nucleotide cofactors NAD and NADH. Together, these molecules 
function to coordinate the maintenance of redox reactions during normal cellular 
metabolism, and act as required substrates for enzymes such as sirtuins (Sirts) and 
poly ADP-ribose polymerases (PARPs). Dietary regimens known to have positive 
effects on age-related health outcomes have been demonstrated to function in 
part through the modulation of NAD/NADH. Most importantly, these nucleotide 
cofactors are required for the maintenance of redox reactions in energy generating 
and energy consuming pathways throughout normal cellular metabolism (i.e., 
glycolysis, TCA-cycle, fatty acid oxidation, electron transport).  
In mammals, the primary site for NAD synthesis is liver; it is produced either 
de novo from tryptophan or through salvage pathways involving the recycling of 
nicotinamide, or nicotinic acid. Nicotinamide phosphoribosyltransferase (Nampt) 
catalyzes the formation of nicotinamide mononucleotide, an immediate precursor 
to NAD and the rate-limiting step in the synthesis of NAD from nicotinamide (Imai, 
2009). Nampt transcription has been shown to follow a circadian rhythm, protein 
abundance oscillating in a pattern that coincides with feeding and fasting (Ramsey 
et al., 2009). However, to date, not much is known about the metabolic signals 
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contributing to Nampt regulation. In liver, glucose and peroxisome proliferator-
activated receptor alpha activation both have been demonstrated to suppress 
Nampt expression through undetermined mechanisms. At the mechanistic level, 
Nampt was identified as an important mediator of lipid metabolism in liver, and a 
direct transcriptional target of hepatic FoxOs.  
In this study, we explored the metabolic landscape of FABP deficiency and 
determined the existence of altered substrate utilization in hepatocytes. We 
provide evidence of metabolic reprogramming in FABP deficiency, marked by 
decreased glucose utilization and enhanced fatty acid oxidation; the latter 
supported by an increase in NAD synthesis via upregulation of rate limiting 
enzyme, nicotinamide phosphoribosyltransferase (Nampt). Furthermore, we 
demonstrate that aP2 inhibits Nampt expression, and exerts additional influence 
on NAD/NADH nucleotide balance by increasing glycolytic rate and suppressing 
fatty acid oxidation. 
 
RESULTS 
Robust impact of FABP deficiency on liver metabolome 
Given the complexity of potential outcomes resulting from the perturbation of a 
single node in a metabolic network, we sought to provide a comprehensive profile 
of metabolites altered in FABP deficiency using metabolomics. For this, we 
employed targeted liquid-chromatography/mass spectrometry (LC/MS) of nearly 
300 metabolite species and analyzed white adipose, plasma, skeletal muscle and 
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liver from wild type and FABP-deficient mice using the web-based metabolomic 
platform, MetaboAnalyst (Xia and Wishart 2011). Comparison of normalized peak 
signals by volcano plot revealed that adipose tissue FABP deficiency evoked only 
minor changes in adipose, plasma, and skeletal muscle, but in liver more than 40% 
of metabolites were altered (Figures 2-1A,B,C,D left panel). 
In order to ascribe discernable physiological roles to each of the liver 
derived factors identified by significance testing and illustrated by heatmapping  
(Figures 2-1A,B,C,D right panel), we utilized the well-annotated metabolite set 
enrichment capabilities of MetaboAnalyst. We found that the metabolite sets 
displaying significant enrichment (red bars) were those related to metabolism of 
protein (i.e., protein biosynthesis, urea cycle, ammonia recycling), citric acid cycle, 
and nicotinate /nicotinamide metabolism (Figure 2-2A). Pathway impact analysis 
was employed to identify metabolite sets with members that reside at highly 
impactful nodes for generation of the relevant product species. Metabolite sets are 
plotted such that those existing highest and closest to the diagonal contain the 
most significant and impactful metabolites (Figures 2-2B).  Based on this analysis, 
nicotinate /nicotinamide metabolism is the most significant and highly impacted 
metabolic pathway in FABP deficiency. 
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Figure 2-1. Global metabolite profiling. 
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Figure 2-1 (Continued). Global metabolite profiling.  
(A-D) All significantly regulated metabolites are represented in adipose, plasma 
and skeletal muscle. For liver, only the top 50 metabolites measured are shown. 
The adjacent pie graphs indicate the percentage of regulated metabolites out of 
those measured.  
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Figure 2-2. Pathway impact analysis of significantly altered metabolites 
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Figure 2-2 (Continued). Pathway Analysis of significantly altered metabolites  
(A) Metabolite enrichment set overview. P value and fold change threshold equal 
to p< 0.05 and 2, respectively.  P value corresponds to significance of fold 
enrichment. Highest significance is indicated in red, lowest is indicated in yellow. 
(B) Pathway impact. In this graphic, as in 3E, the color signifies pathway 
significance based on p-value threshold <0.05. Circle size indicates magnitude of 
pathway impact. 1) Nicotinate /nicotinamide metabolism, 2) Arginine and proline 
metabolism, 3) Pyrimidine metabolism, 4) Ala, Asp, Glu metabolism, 5) Citric acid 
cycle. 
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Liver nicotinamide metabolism and NAD/NADH ratio is altered in FABP deficiency 
Nicotinate and nicotinamide are important precursors for the production of NAD, 
an essential nucleotide and a vital co-factor in the catabolism of lipids, 
carbohydrates, and proteins. For this reason, we used qPCR to examine hepatic 
gene expression of enzymes involved in producing NAD, requiring either 
nicotinate, nicotinamide, or the de novo precursor, tryptophan. Adipose FABP 
deficiency led to increased expression of de novo NAD synthesis enzymes, 
tryptophan dioxygenase (1.6-fold), and NAD synthase (2-fold, p<0.01) (Figure 2-
3A). Contribution of the nicotinate salvage pathway to cellular NAD levels is 
considered relatively minor, and accordingly we determined no significant 
regulation of nicotinic acid phosphoribosyltransferase (Naprt), an enzyme specific 
to this arm (Figure 2-3A). On the other hand, Nampt, a rate-limiting enzyme of the 
nicotinamide salvage pathway and main route for NAD synthesis in mammals was 
significantly upregulated (1.8-fold, p<0.05). Given that nicotinate /nicotinamide 
metabolism was identified as the most highly impacted metabolite set, and we did 
not detect significant gene regulation of the nicotinate pathway, we focused on 
the NAD salvage pathway requiring Nampt. 
Analysis of known transcriptional regulators of Nampt expression revealed 
significant increases of Foxo1, PGC1α and Bmal in liver of FABP deficient mice. (Liu 
2007, Ramsey 2009) (Figure 2-3B). Together, these transcription factors integrate 
metabolic signals and the molecular clock machinery corresponding to circadian 
rhythm, in an effort to maintain stability between nutrient availability and cellular 
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energy demands. In the fed state, Nampt protein levels were increased in aP2-
mal1-/- mice compared to wild type (Figure 2-3C), which was concordant with gene 
expression data (Figure 2-3A). Nampt protein levels highly reflect the cellular 
energy status, and normally become elevated upon fasting in vivo, or glucose 
withdrawal in vitro (Imai 2000). However, aP2-mal1-/- mice maintained a 
constitutively high level of Nampt protein independent of fed status, comparable 
to wild type levels in the fasted state (Figure 2-3D). Furthermore, the immediate 
product of Nampt catalytic activity and the precursor to NAD, nicotinamide 
mononucleotide, was present at high levels compared to wild type in both the fed 
and fasted state. 
Elevated levels of Nampt in aP2-mal1-/- animals is perhaps indicative of an 
attempt to both restore NAD levels to avoid depletion during excessive 
consumption and to eliminate excess nicotinamide, an inhibitor of NAD 
consuming enzymes (Figure 2-3F) (Revollo et al., 2007). To explore this possibility, 
we first measured nucleotide concentrations using a fluorometric assay to 
determine the status of oxidized (NAD+) and reduced (NADH) forms of NAD. FABP 
deficiency resulted in an overall increase in the total pool of nucleotide (Figure 2-
3G). However, NAD+ content was lowered in aP2-mal1-/- mice (mean difference 
from wild type, -2.648 ± 0.4 nM/µg protein, p<0.001), and was accompanied by a 
concomitant increase in NADH (mean difference from wild type, 18.10 ± 2 nM/µg 
protein, p<0.001) (Figure 2-3H), corresponding well with the metabolomics data. 
Interestingly, altered NAD/NADH ratios have been suggested to underlie the 
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effects of dietary restriction in increasing healthspan (Imai 2009).  Specifically, a 
reduced NAD/NADH ratio largely driven by an increase in NADH levels was 
reported in livers of dietary-restricted mice (Chen et al., 2008). Here, we observe a 
similar trend in FABP deficiency, along with other features common to metabolic 
reprogramming events. With this in mind, we also considered the role of NAD 
consumption in this process. First, we selected two well-described NAD consuming 
enzymes to examine: Sirtuin1, and poly-ADP ribose polymerase (PARP). Sirt1 
couples NAD cleavage to the deacetylation of protein substrates (Vaziri et al., 2001) 
and PARP transfers ADP-ribose from NAD to itself and other nuclear proteins at 
sites of DNA single strand breaks to signal repair (Charron and Bonner-Weir, 1999). 
The potential for PARP to regulate NAD levels greatly outweighs that of Sirtuins, 
given that the later consume only one molecule of NAD per reaction while PARP 
has the capacity to generate polymers comprised of hundreds of ADP ribose 
moieties. Thus, we determined gene expression using qPCR and functional outputs 
of Sirtuin and PARP activities using a fluorometric enzyme assay and western blot 
of ADP-ribosylated proteins, respectively. While mRNA levels of both Sirt1 and 
PARP were elevated (Figure 2-4A), poly ADP-ribosylation was increased in FABP 
deficiency (Figure 2-4B) but Sirtuin-mediated deacetylation was not (reaction rates, 
387.1±12.5 and 382.5±7.5, WT and aP2-mal1-/-, respectively) (Figure 2-4C). Taken 
together, these observations signify that FABP deficiency evokes an increase in 
total nucleotide levels through transcriptional upregulation of the rate-limiting 
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NAD synthesis gene Nampt, while shifting the predominant species from NAD to 
NADH. 
 
Citric acid cycle activation contributes to altered NAD/NADH ratio 
NADH, typically produced during macronutrient catabolism, is a marker for carbon 
flux through the citric acid cycle, providing reducing equivalents to drive 
mitochondrial electron transport for ATP synthesis. Our data points to a nucleotide 
imbalance having potential effects on both substrate availability and substrate 
utilization. Indeed, there is a substantial impact on citric acid cycle pathway gene 
activation (Figure 2-5A) and a marked increase in the corresponding levels of citric 
acid cycle metabolites (Figure 2-5B). With the exception of citrate synthase and 
alpha-ketoglutarate dehydrogenase, all enzymes of the citric acid cycle are 
elevated between 1.5 to 2 fold, as determined by qPCR array (Figure 2-5A) 
Additionally, pathway intermediates were elevated between 1.5 and 4 fold (Figure 
2-5B). Notably, all of the metabolites that directly participate in redox-reactions 
producing NADH were increased by several fold in aP2-mal-/- mice.  
Although citric acid cycle activation provided a means to explain the high 
levels of NADH present in FABP deficient livers (Figure 2-3H), two fundamental 
questions remained. First, why has this switch in redox status occurred? Secondly, 
what impact does this alteration in nucleotide ratio have on liver metabolism? 
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Figure 2-3. NAD metabolism in Liver. 
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Figure 2-3 (Continued). NAD metabolism in Liver.  
(A) qPCR of genes encoding enzymes involved in each of the three pathways for 
NAD production and (B) transcription factors regulating Nampt. (C) N=4. (D) 
Immunoblot of rate limiting enzyme of NAD synthesis, Nampt in random fed 
animals, and (E) animals in the fed and fasted state. (E) Levels of nicotinamide 
mononucleotide, the immediate product of Nampt activity. (F) Graphical 
representation of NAD salvage pathway from nicotinamide. (G-H) Total nucleotide 
levels (G) as nanomolar ratios and (H) as separate species. Abbreviations: 
tryptophan dioxygenase (TDO), quinolinate phosphoribosyltransferase (Qaprt), 
nicotinamide/nicotinate mononucleotide adenylyltransferase (Nmnat), NAD 
synthetase (Nadsyn), nicotinic acid phosphoribosyltransferase (Naprt), 
nicotinamide phosphoribosyltransferase (Nampt). * p<0.05, **p<0.01. 
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Figure 2-4. NAD consumption in FABP deficiency. (A) qPCR of NAD consuming 
enzymes, (B) Immunoblot of poly-ADP ribosylated proteins and an H2O2 treated 
HeLa cell lysate as a positive control. Line indicates range of 116-200kD 
corresponding to ribosylated proteins. (C) Sirtuin protein levels (left) and 
deacetylase activity (right) in 10 μg of liver lysate. Graph includes linear portion of 
60-minute assay. Recombinant-Sirt1 was assayed +/- NAD as a positive control.  N = 
3-4, 12 weeks of age for each genotype. 
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Figure 2-5. Citric acid cycle pathway activation. (A) Citric acid cycle gene 
expression as determined using SAB biosciences qPCR array on pooled cDNA from 
each genotype. (B) Heatmap of TCA cycle intermediates in aP2-mal1-/- versus wild 
type. 
0.0 0.5 1.0 1.5 2.0 2.5
malate dehydrogenase
fumarate hydaratase
succinate dehydrogenase
succinyl-CoA synthetase
a-ketoglutarate dehydrogenase
isocitrate dehydrogenase
aconitase
citrate synthase
pyruvate carboxylase
fold change of WT
NADH 
NADH 
NADH 
Acetyl-CoA 
TCA Cycle 
Isocitrate 
α-ketoglutarate 
 
Succinate 
Malate 
Fumarate 
Oxaloacetate Citrate 
416706.6 411700.5 337882.7 539251.9 
 WT 
1787470.1 1347989.9 1636764 1108078.7 
 KO 
163239.69 105196.15 122062.43 58721.72 
 WT 
195474.91 204958.12 256288.34 294973.89 
 KO 
 WT 
4131.023 10619.6 9738.897 4131.023 
 KO 
20102.054 24561.049 31069.239 16366.54 
 WT 
  6282034.799 9506014.012 7237550.448 
 KO 
  7088325.324 8451746.898 11517571.43 
 WT 
120431.62 57202.36 52122.96 38978.75 
 KO 
154515.3 173593.23 186624.21 241836.55 
 WT 
2048350.865 1689963.141 1866177.77   
 KO 
2473939.036 2636336.996 3079714.34   
184335.5 272450.3 218264.3 285877.1 
 WT 
241315.7 232897 187999.9 375528.2 
 KO 
Succinyl-CoA 
150010.6 137411.6 108295.9 211495 
 WT 
410493.4 471801.5 518439.2 612754.8 
 KO 
3.5x 
2x 
3x
3x 1.5x 
4x 
A 
B 
 WT 1 2 3 4
aP2-mal1-/- 1 2 3 4
1 2 3 4
low high
animal #
Chapter 2 Adipose tissue FABP deficiency profoundly impacts liver NAD metabolism    
 
	   40 
Metabolic reprogramming in FABP deficiency 
Harvesting energy from nutritional substrates and stored macromolecules requires 
a series of steps that generate carbon units to be processed through the citric acid 
cycle. For small mammals, metabolic cage experiments are used to determine 
substrate utilization. In this type of experiment, O2 intake and CO2 produced from 
macronutrient catabolism are measured. From this, a respiratory exchange ratio 
(RER) is determined, representing the stoichiometric relationship between the 
amount of oxygen required and the amount of CO2 produced in the complete 
oxidation of one mole of carbohydrate  (RER = 1.0) or one mole of lipid (RER = 0.7). 
Using this standard method, we calculated the RER value over a 12-hour dark 
period. We found that there is a marked difference in the frequency distribution of 
RERs between wild type and aP2-mal1-/- mice across all intervals (Figure 2-6), with 
FABP deficiency causing a leftward shift towards lower RERs, suggesting an 
alteration of substrate preference from carbohydrates to fatty acids. [Determining 
substrate utilization from this value can however be complicated by two factors. 
First, highly glycolytic tissues release lactate into circulation leading to a rise in pH, 
necessitating the conversion of HCO3 to CO2 in a deacidification reaction. Having 
previously documented enhanced muscle glucose uptake in aP2-mal1-/- mice 
(Maeda et al., 2005), it seemed likely that these RER values could also reflect a 
measure of discordant CO2 production in FABP deficient mice. Secondly, proteins 
cannot be completely oxidized to CO2, thus it is difficult to attribute a single RER 
value to protein catabolism. However, given that protein catabolism is commonly 
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Figure 2-6. Evidence of altered substrate utilization in FABP deficiency. 
Respiratory exchange ratios. VO2 and VCO2 gas exchange was measured over a 72-
hour period. Plot represents frequency distribution of RERs recorded at 10-minute 
intervals over a 12-hour dark cycle. N = 4 per group. 
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regarded as a minor contributor to overall carbon flux under normal conditions, 
the inaccuracy associated with metabolic cage determination of substrate 
utilization, with respect to protein, is considered negligible and not accounted for. 
If indeed the case, blood buffering of lactate and/or activation of protein 
catabolism in FABP deficiency would lead to a significant overestimation of RER, 
and therefore, an underestimation of the fatty acid oxidation contribution to 
cellular respiration. 
Given the caveats of metabolic cage monitoring, we explored the possible 
contribution of blood buffering and protein catabolism to RER in FABP deficiency. 
Lactate produced by highly glycolytic skeletal muscle is delivered to liver through 
the circulation to the liver, where it is metabolized. LC/MS analysis of lactate, 
however, revealed no apparent activation of this cycle in FABP deficiency, as 
skeletal muscle, plasma and liver lactate levels were comparable between both 
genotypes (Figure 2-7A). We then asked whether protein catabolism was activated 
in FABP deficiency by investigating the urea cycle, as ammonium released during 
protein deamination enters this pathway to be processed for excretion. While 
expression of ornithine transcarbamylase (OTC), arginosuccinate synthase 1 (ASS1), 
and arginosuccinate lyase (ASL) were all modestly elevated, OTC was the only urea 
cycle enzyme gene to reach a statistical increase in aP2-mal1-/- livers (Figure 2-7B 
and C). Additionally we found that Sirt3, which promotes urea cycle activity by 
deacetylation of OTC, was also modestly increased though not significantly (Figure 
2-7B). (Hallows et al., 2011). Regarding activating metabolites of the urea cycle, N- 
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Figure 2-7. Activation of Protein Catabolism. (A) Lactate levels in skeletal 
muscle, plasma and liver, corresponding to the Cori cycle. (B) Gene expression of 
urea cycle enzymes. (C) Urea cycle intermediates increased in aP2-mal1-/- vs. WT are 
circumscribed by solid red line (≥ 1.5-Fold). (D) Amino acid mediated citric acid 
cycle anaplerosis. Fold Change (Log2) indicates magnitude of increase in amino 
acids leading to production of α-ketoglutarate .  
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acetylglutamate and arginine were both increased in FABP deficient livers, by 4-
fold and 7-fold, respectively (Figure 2-7C). Ornithine, another key intermediate in 
the urea cycle, achieved the highest fold increase (13-fold) of the 208 metabolites 
that were detected in liver, and was among several other enhanced cycle 
intermediates (Figure 2-7C). An important mechanistic feature of urea cycling, 
parallel to the detoxification of nitrogen generated from protein catabolism, is 
anaplerosis—the replenishment of citric acid cycle intermediates for the 
generation of NADH. Accordingly, all alpha-ketoglutarate related amino acids are 
present at high levels in aP2-mal1-/- livers (Figure 2-7D). This substrate-driven 
activation of the urea cycle underscores a dominant role for proteins in the 
replenishment of energy substrates in FABP deficiency. Adding further strength to 
this idea is the fact that pathways relevant to protein metabolism appeared high 
on both the metabolite enrichment and pathway impact scales, ranking adjacent 
to citric acid cycle, and nicotinamide metabolism (Figure 2-2A and B). Remarkably, 
though protein catabolism is known to predominate during high intensity exercise 
or prolonged fasting, FABP deficiency alone mimics the same pathway activation. 
To determine the nature of this switch in substrate preference from 
carbohydrates to fatty acids revealed by the left-shift in RER frequency distribution, 
we examined glycolysis and fatty acid oxidation pathways. Glycolytic gene 
expression, protein levels of glucose transporter 2, and metabolites of glycolysis 
were all decreased in FABP deficient mice (Figures 2-8A,B,C). Conversely, 
expression of genes known to play a critical role in regulating mitochondrial 
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uptake of fatty acids and subsequent β-oxidation, CPT1α and Acadm, respectively, 
were each elevated by two-fold (Figures 2-8D and E). 
Through this comprehensive analysis of the liver metabolome, we have 
confirmed enhanced activation of β-oxidation, and revealed a previously unknown 
phenotype of FABP deficiency: protein-mediated citric acid cycle anaplerosis. This 
alternative pathway activation likely contributes to an enhanced rate of NADH 
production, and improved homeostatic control when FABP deficiency is coupled 
with genetic or diet induced obesity. Together, these data allow us to assign a 
probable cause and source of the NAD/NADH nucleotide imbalance demonstrated 
in aP2-mal1-/- mice.  
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Figure 2-8. Metabolic shift from glucose utilization to lipid oxidation 
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Figure 2-8 (Continued). Metabolic shift from glucose utilization to lipid 
oxidation (A-C) Glucose metabolism. (A) Glycolytic gene expression as in figure 3A. 
(B) Glut2 protein levels and (C) heatmapping of glycolytic intermediates using 
same scale as figure 3b. Fatty acid oxidation. (D) Expression of critical genes for 
mitochondrial fatty acid uptake and oxidation, CPT1α and Acadm. (E) Acetyl-CoA 
levels. 
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aP2 influences substrate preference in hepatocytes 
Since FAPB deficiency critically impacts substrate utilization in liver, and 
given that aP2 is a bona fide adipokine, we then asked whether aP2 itself could 
influence carbohydrate and/or lipid metabolism in a liver cell line. We first 
established that the effect of FABP deficiency on liver substrate utilization was non 
cell-autonomous, as primary hepatocytes isolated from wild type and aP2-mal1-/- 
mice responded similarly to a functional test of cellular respiration when exposed 
to glucose, palmitate, or glutamine (Figure 2-9A). Primary hepatocytes from the 
two genotypes also expressed comparable levels of Nampt (Figure 2-9B). 
Therefore, the effect of FABP deficiency on liver as demonstrated in Figure 2-3A is 
essentially lost in hepatocytes isolated from systemic metabolism.  
We then pre-incubated Hepa1-6 cells with aP2 protein for 4 hours and then 
exposed them to either glucose or palmitate in the continued presence of aP2. 
Quite strikingly, aP2 increased glycolytic rate (Figure 2-10A) and decreased the rate 
of fatty acid oxidation (Figure 2-10B), both in a dose dependent manner. Recalling 
the effect of FABP deficiency on NAD/NADH levels, it seemed likely that these 
outcomes could be the consequence of an altered redox environment. Indeed, aP2 
treatment moderately reduced total nucleotide levels (Figure 2-10C), and induced 
a dramatic shift of the ratio in favor of the oxidized form (Figure 2-10C). These data 
support the idea that aP2-mediated inhibition of fatty acid oxidation contributes to 
a substantial reduction in NADH and follows a model whereby FABP deficiency 
allows for higher rates of fatty acid catabolism and subsequent NADH production. 
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Figure 2-9. Cell non-autonomous regulation of liver substrate utilization.  
Primary hepatocytes were isolated from wild type and aP2-mal1 deficient mice. (A) 
Cellular respiration was measured after exposure to energy substrates. (B) 
Expression of Nampt was measured at three time points after isolation. 
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Figure 2-10. aP2 directs substrate utilization and alters nucleotide levels. 
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Figure 2-10 (Continued). aP2 directs substrate utilization and alters 
nucleotide levels. (A) Hepa1-6 cells pre-incubated with increasing concentrations 
of aP2. (A) Extracellular Acidification Rate (ECAR) is measured in response to 
glucose. (B) Oxygen Consumption Rate (OCR) is measured in response to palmitate. 
ECAR and OCR correspond to glycolytic rate and fatty acid oxidation, respectively. 
Graphs adjacent to 4A and 4B represent the area under the curve (AUC) for each 
measurement at the highest concentration of aP2 (9ug/mL) (C) Total nucleotide 
graphed as nanomolar ratios and separate species. 
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aP2 regulates hepatic Nampt in vitro and in vivo 
Recently, Tao et al. reported that a liver specific knockout of FOXOs 1,3 and 4 
exhibited hepatic steatosis that was accompanied by insufficient liver Nampt 
expression. Furthermore, this group demonstrated that adenoviral mediated 
overexpression of Nampt reversed this phenotype, as evidenced by decreased 
hepatic lipogenesis, a high rate of fatty acid oxidation and lower liver triglycerides. 
Taken together, these data suggest that Nampt modulates NAD levels in the 
regulation and maintenance hepatic lipid metabolism. As our findings suggest a 
role for FABPs in the regulation of nucleotide levels and fatty acid metabolism, we 
sought to experimentally determine a role specifically for aP2 in these processes.   
To link aP2 function to the regulation of Nampt, we incubated Hepa 1-6 cells 
expressing a Nampt-luciferase promoter construct with mouse serum collected 
from wild type and aP2-mal1-/- mice. aP2-mal1-/- serum activated the Nampt 
promoter reporter and expression of endogenous Nampt protein to a greater 
extent than wild type (Figure 2-11A and B). These findings suggest that a 
component present in wild type serum suppresses Nampt transcription, and we 
hypothesized that the adipokine aP2 could play this role. To investigate this 
possibility, we employed the use of chemical (aP2i)- and antibody (aP2H3)- based 
inhibitors with demonstrated specificity for aP2 (Furuhashi and Hotamisligil, 2008). 
Both inhibitors of aP2 relieved the suppressive effect of wild type serum on Nampt 
promoter activity, which was restored to the same level as that measured in cells 
incubated with aP2-mal1-/- serum (Figure 2-11C).  
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To more specifically demonstrate that adipose tissue aP2 was responsible 
for this activity, we co-incubated Hepa 1-6 cells with differentiated adipocytes 
using the Transwell system. Again, we observed a repressive effect on Nampt 
transcription in cells co-cultured with adipocytes from mice with wild type levels of 
aP2, but not in cells co-cultured with adipocytes from aP2-mal1-/- mice (Figure 2-
11D). Furthermore, we can recapitulate this negative regulation observed in the 
Hepa 1-6/WT adipocyte condition by addition of aP2 protein to the Hepa 1-6/AM-/- 
co-culture, leading to a deficiency in Nampt protein expression (Figure 2-11E). 
Lastly, we can counteract this effect, and restore Nampt protein levels by addition 
of aP2i or aP2H3 inhibitors (Figure 2-11E). 
To support earlier findings that Nampt inhibition reduces fat oxidation, and 
to provide additional support for aP2 as an upstream negative regulator of Nampt, 
we employed a commonly used inhibitor of Nampt activity, FK866. As expected, 
both aP2 protein and FK866 inhibited palmitate oxidation, while dual exposure 
produced no added effect (Figure 2-12A and B). We also provided cells with the 
NAD pathway intermediates nicotinamide, and nicotinamide mononucleotide, 
which lie immediately up and downstream of Nampt activity, respectively. Hepa 1-
6 cells were refractory to nicotinamide supplementation, however, the addition of 
nicotinamide mononucleotide reversed aP2-induced inhibition of palmitate 
oxidation (Figure 2-12C). 
Finally, we could reliably recapitulate the effects of Nampt inhibition in vivo 
by intravenous administration of aP2 protein. After six hours of infusion, we were 
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able to detect a significant reduction in both Nampt mRNA and protein (Figure 2-
11F and G). Furthermore, this effect was specific for Nampt, as there was no effect 
on gene expression of other key enzymes involved in NAD metabolism. This 
finding, together with in vitro data utilizing Hepa 1-6 cells exposed to mouse 
serum, co-cultured adipocytes, and recombinant aP2 solidifies aP2 as a negative 
regulator of Nampt expression (Figure 2-11H).  
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Figure 2-11.  Suppression of Nampt by aP2 in vitro and in vivo. 
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Figure 2-11 (Continued).  Suppression of Nampt by aP2 in vitro and in vivo. (A) 
Luciferase activity and (B) Nampt protein levels in Hepa 1-6 cells transfected with a 
Nampt-luciferase reporter construct exposed to either wild type or aP2-mal1-/- 
mouse serum. (C) Luciferase activity in cells treated in same manner as figure 5A 
and 5B with the addition of aP2 chemical inhibitor (aP2i) or aP2 antibody (aP2H3). 
(D) Hepa 1-6 cells co-cultured for 18 hours with differentiated adipocytes, or Hepa 
1-6 cells as a control. (E) Nampt protein levels in Hepa 1-6 cells co-cultured with 
differentiated aP2-mal1-/- adipocytes exposed to aP2 protein in the presence and 
absence of aP2i and aP2H3. (F) Hepatic gene expression of NAD biosynthesis 
genes, and (H) protein levels of liver Nampt after 6 hour intra venous infusion of aP2 
protein into aP2-mal1-/- mice. 
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Figure 2-12. Inhibition of palmitate oxidation by aP2 and small molecule 
inhibitor of Nampt. (A-B) OCR in Hepa 1-6 cells exposed to aP2 protein or FK866 
for 4 hours. (C) Area under the curve of OCR after exposure to aP2 in the presence 
of NAD pathway metabolites.  
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DISCUSSION 
Besides achieving satiety, the major purposes of food intake are to provide 
sufficient sources of carbon for the generation and maintenance of biological 
structures, and to meet the variable need for storage and supply of energy. De 
novo synthesized lipids, carbohydrates, and proteins, accompanied by a milieu of 
metabolites and hormonal signals all together comprise a critical and 
complimentary exchange mechanism between intrinsic factors and dietary inputs. 
Hormones allow for adaptation to acute perturbations in substrate levels. 
For example, insulin secreted in response to increased plasma glucose directs its 
uptake into peripheral tissues, and liver responds by activating glycolytic and 
lipogenic transcriptional programs. On the other hand, sustained alterations in 
substrate availability or utilization capacity challenge the ability of an organism to 
meet energy demands. We have previously shown that a combined deficiency of 
aP2 and mal1 protects from hepatic steatosis and improves glucose homeostasis 
by down-regulating the lipogenic and glucogenic programs in liver  (Maeda et al., 
2005, Cao et al., 2013). Given that these pathways are inextricably linked to the 
storage and utilization of energy required for normal cellular maintenance, we 
aimed to understand the impact of these regulatory changes on hepatic 
metabolite flux. One limitation of mechanistic studies involving metabolic 
phenotypes is an incomplete knowledge of which substrates are available for 
catabolism and whether there is preferential usage among those available 
substrates. As is the custom in the field, we regularly assess substrate availability by 
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measuring concentrations of substrates most proximal to energy production (i.e., 
glucose and major classes of lipids) and perhaps link data with respiratory 
exchange ratios determined from metabolic cage experiments to determine 
utilization. These data however, are only a fractional representation of metabolite 
flux and extrapolations towards substrate utilization from these experiments lack 
sufficient resolution to address complex phenotypes. Given the centrality of lipids 
to metabolism and the ability of fatty acid binding proteins to influence multiple 
levels of systemic regulation, we sought to provide a comprehensive profile of 
metabolites altered in FABP deficiency using metabolomics. LC/MS revealed a 
dramatic reprogramming of metabolite flux in liver as evidenced by the 
enrichment of metabolites associated mainly with nicotinamide metabolism, 
amino acid deamination and ammonia detoxification. Although usually considered 
to be relevant only under prolonged fasting conditions, proteins can be mobilized 
to generate energy substrates by liberating glucogenic, ketogenic, and anaplerotic 
amino acids. To achieve this, the liver forms alpha-ketoacids by the deamination of 
proteins, and utilizes the resultant carbon skeletons to generate acetyl-CoA, 
pyruvate, or citric acid cycle intermediates. We suggest that this process is initiated 
to fuel citric acid cycle intermediates in response to a dampening of glycolysis and 
increased acetyl-coA produced from fat oxidation. Moreover, we provide evidence 
that that urea cycling contributes mainly to the replenishment of citric acid cycle 
intermediates for the production of NADH. 
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The constitutively high levels of liver Nampt protein and hepatic nucleotide 
imbalance we observe each bear a remarkable resemblance to dietary restriction, 
an intervention known to extend healthspan and longevity in a variety of 
organisms, including primates (Colman et al., 2009). The adaptive response to 
dietary restriction involves suppression of glycolysis, enhanced liver 
gluconeogenesis and glucagon-stimulated degradation of glycogen stores in order 
to maintain glucose levels. Over time, insufficient availability of carbohydrates will 
stimulate lipolysis and trigger the mobilization of lipids from adipose tissue 
(Dhahbi et al., 2001). Upon depletion of fat stores, the organism is then forced to 
catabolize muscle protein for use as an energy substrate. Remarkably, ad libitum 
fed mice deficient in FABPs are able to access pathways associated with long term 
dietary restriction, yet, are resistant to the wasting of skeletal muscle and 
peripheral tissue that occurs during starvation (Gabriely and Barzilai, 2001). 
A key defining feature of FABP deficiency, also mimicking dietary restriction, 
is reduced adipose tissue mass, a feature that becomes even more pronounced 
when mice are challenged with a high fat diet. (Hotamisligil et al., 1996; Maeda et 
al., 2005). We propose a model whereby FABP deficiency allows for more effective 
utilization of fat by hepatocytes. High levels of β-oxidation, and the nearly two-fold 
increase in acetyl-CoA, each provide an abundance of carbon units for entry into 
the citric acid cycle. We found that in order to accommodate entry of large 
amounts of acetyl-CoA, citric acid cycle anaplerotic mechanisms were activated in 
FABP deficiency, marked by a substantial increase in urea cycle intermediates and 
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elevated anaplerotic amino acids. Our previous studies indicate that 
gluconeogenesis, a pathway that requires NADH, is suppressed livers of aP2-mal1-/- 
mice. It is likely then, that the coupling of decreased gluconeogenesis with 
increased citric acid cycle activity favors high NADH. Consistent with this reduced-
state cellular environment in FABP deficiency was an inhibitory effect on the 
glycolytic pathway. Together, these findings demonstrate that FABP deficiency 
somewhat mimics dietary restriction by permitting more efficient fat utilization 
while also diminishing the activity of glucose-dependent energy generating 
pathways. Moreover, we demonstrate the ability of adipose derived aP2 to engage 
biochemical pathways in hepatocytes that direct substrate utilization resulting in 
an increased rate of glycolysis, and suppression of fatty acid oxidation. Our data 
indicates that FABPs conduct a major role in the communication of nutritional 
status between adipose and liver, and that their absence contributes to 
reprogramming of hepatic substrate metabolism in a manner that mimics the 
effects fasting. 
It is well known that NAD cycles between both oxidized and reduced forms 
during cellular energy metabolism, though more recently it has also been shown 
to be consumed by reactions that transfer the ADP-ribose moiety to additional 
targets, or by enzymes that couple NAD cleavage to their catalysis (Mattevi, 2006). 
The existence of a second regulatory role for NAD underscores the potential 
influence of not only NAD biosynthesis enzymes, but also of NAD consuming 
enzymes on glucose utilization, fatty acid metabolism, and subsequent substrate 
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transformations involving redox reactions. Through our in vitro modeling of an 
adipo-hepatic regulatory axis utilizing mouse serum, liver cell/adipocyte co-
culture, we have established aP2 as a negative regulator of Nampt expression 
(Figure 5H). Infusion of aP2 protein into aP2-mal1-/- mice confirmed that this 
regulatory model also applies to metabolism in vivo.  
The emerging facts indicate that the benefits of longevity result from a 
delayed development of age-related diseases in mammals, many of which have 
known causal links to metabolism such as type 2 diabetes, cancer and 
cardiovascular disease (Hursting et al., 2001; Lane et al., 1999; Manco and 
Mingrone, 2005). Despite much attention surrounding the life extending effects of 
dietary restriction, the factors mediating the relationship between a restrictive diet 
and postponement of these outcomes remain largely elusive. We have previously 
shown protection against the deleterious effects of high-fat diet in FABP 
deficiency, including resistance to hepatic steatosis accompanied by a substantial 
increase in muscle glucose uptake (Cao et al., 2008). Here we demonstrate that 
genetic deficiency of aP2 re-directs substrate utilization towards fatty acid 
oxidation rather than glycolysis, thus opposing the canonical energy substrate 
preference of liver. It is therefore likely that the protective phenotype 
demonstrated by FABP deficient mice on high fat diet is due, at least in part, to a 
heightened capacity for fatty acid oxidation. 
Our current findings, together with previous observations validate the 
designation of aP2 as a desirable therapeutic target—An adipocyte derived 
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circulating factor that exhibits a specialized role in regulating hepatocyte function 
while having minimal impact on the metabolome at additional sites in the 
periphery.  
 
MATERIALS AND METHODS 
aP2-mal1-/- mouse model 
Mice with combined aP2-mal1 deficiency were generated from an intercross 
between C57BL/6J-aP2−/− and C57BL/6J-mal1−/− mice (Maeda et al., 2005). Both aP2 
and mal1 expression were undetectable in adipose tissue depots. Furthermore, 
there was no compensatory upregulation of other FABP isoforms in adipose tissue 
of aP2-mal1 deficient mice. 
 
Targeted Liquid-Chromatography Mass Spectrometry (LC/MS) 
100 mg of tissue samples were homogenized in 1ml of 80% v/v methanol.   
Insoluble material in lysates was centrifuged at 14,000rpm for 15 minutes and 
resulting supernatant was evaporated using a refrigerated speed-vac.  Samples 
were re-suspended using 20uL HPLC grade water for mass spectrometry at Beth 
Israel Deaconess Medical Center mass spectrometry core facility. 10μL were 
injected and analyzed using a 5500 QTRAP triple quadruple mass spectrometer 
(AB/MDS Sciex) coupled to a Prominence UFLC HPLC system (Shimadzu) via 
selected reaction monitoring (SRM) of a total of 249 endogenous water soluble 
metabolites for analyses of samples.  Some metabolites were targeted in both 
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positive and negative ion mode for a total of 298 SRM transitions.  ESI voltage was 
5000V in positive ion mode and –4500V in negative ion mode.  The dwell time was 
5 ms per SRM transition and the total cycle time was 2.09 seconds.  Samples were 
delivered to the MS via normal phase chromatography using a 2.0 mm i.d x 15 cm 
Luna NH2 HILIC column (Phenomenex) at 285 μL/min.  Gradients were run starting 
from 85% buffer B (HPLC grade acetonitrile) to 42% B from 0-5 minutes; 42% B to 
0% B from 5-16 minutes; 0% B was held from 16-24 minutes; 0% B to 85% B from 
24-25 minutes; 85% B was held for 7 minutes to re-equilibrate the column.  Buffer A 
was comprised of 20 mM ammonium hydroxide/20 mM ammonium acetate in 95:5 
water: acetonitrile.  Peak areas from the total ion current for each metabolite SRM 
transition were integrated using MultiQuant v1.1 software (Applied Biosystems).  
Glucose-13C labeled samples were run with 249 total SRM transitions (40 in 
positive ion mode and 209 in negative ion mode) with a total cycle time of 0.464 
seconds. Data processing, statistical analysis, and pathway mapping was 
performed using the internet based platform, MetaboAnalyst (Xia and Wishart 
2011). 
 
Quantitative PCR and Western blotting 
Total RNA was isolated from 100 mg of tissue using Trizol reagent. cDNA synthesis 
was performed using BioRad 5x iscript supermix. SYBR green based qPCR was 
performed on an ABI Thermocycler Primer sequences available as supplementary 
information. Western blots were prepared from SDS-PAGE gels as previously 
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described. Polyclonal antibody anti-Nampt (PBEF) (abcam ab45890). Monoclonal 
anti-PAR Polymer antibody (BD Pharmingen). Glut2  (Santa Cruz SC-9117). Sirt1 
(Millipore 07-131). β-tubulin HRP (abcam ab21058). 
 
NAD/NADH nucleotide levels 
Livers were collected from exsanguinated mice was homogenized in either NAD or 
NADH extraction buffers—30 mg tissue each. Nucleotide concentrations were 
determined using a fluorescent NAD/NADH detection kit according to 
manufacturer’s protocol (Cell Technology, Inc # FL NADH 100-2).  
 
Glycolysis and Fatty Acid Oxidation measurements 
Extracellular acidification rate and oxygen consumption rate were measured in 
Hepa 1-6 cells using the XF96 extracellular flux analyzer from Seahorse Bioscience. 
Cells were seeded at a density of 10K cells per well one day prior to assay in 
complete media. For the assay, cells were exposed to XF assay media 
supplemented 5mM glucose and 1% serum. OCR values represent Palmitate OCR 
minus BSA OCR.  
 
Cell culture studies 
Hepa1-6 were cultured in DMEM supplemented with 10% CCS and antibiotics. 
Nampt-luciferase reporter construct was a kind gift from the laboratory of Charlie 
Dong (Indiana University). Mouse blood was collected from FABP-deficient mice 
after 6-hour daytime food-withdrawal, using terminal blood collection by cardiac 
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puncture. After 20-30 minutes of clotting time on ice, samples were centrifuged for 
20min at 8000 rpm, 40C. After removal of clotting factors, serum will be collected 
and stored at –800C. Mouse serum was pooled from 8 mice and supplemented at a 
concentration of 18%.  Preadipocytes were differentiated using standard methods. 
 
Sirtuin deacetylase activity 
Activity measurements were made using Cyclex Sirt1 deacetylase fluorometric 
assay kit according to manufacturers protocol. (Cyclex, CY-1151). Briefly, Livers 
were homogenized in 10-fold volume Modified RIPA Buffer minus protease 
inhibitors. Using a 50µl reaction volume, appearance of the deacetylated 
fluorescent substrate was measured at one-minute intervals for 30 minutes using 
SoftMax Pro microplate reader at excitation and emission wavelengths of 340 and 
440nm, respectively. Assay Buffer: 50mM Tris-HCl, pH8.8, 4mM MgCl2, 0.5mM DTT, 
50X Fluoro-Subsrate Peptide, 5mAU/mL lysyl endpeptidase, 10X Trichostatin A, 
2mM β –NAD. 
 
Primary hepatocyte isolation 
Mice were anesthetized using a ketamine/xylene mixture, and perfused through 
the hepatic portal vein with 20 mL of Hank’s Balanced Salt Solution (HBSS) buffer 
warmed to 400C at a rate of 1.8 mL/minute. Following this, the liver is perfused with 
20 mL of HBSS buffer containing collagenase (HBSS+) at the same rate. The liver 
was excised and transferred to a petri dish containing 5 mL of HBSS+ on ice, and 
cells were dispersed using forceps. This cell suspension was transferred to a tube 
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containing 35 mL of DMEM + 10% calf serum and subsequently filtered through a 
70 µM cell strainer. The hepatocytes were centrifuged at 500rpm for 1 minute, 
washed once with DMEM and centrifuged again at 500 rpm for 1 min. The cell 
suspension was overlaid with 40% percoll in PBS and centrifuged at 800rpm for 10 
min. Cells were re-suspended in William’s E media and plated onto collagen coated 
plates. 
 
Intra venous aP2 infusion 
Mice with combined aP2-mal1 deficiency were reconstituted with aP2 by infusing 
recombinant protein into a jugular vein catheter at a dose of 8μg/kg/min. Intra 
venous aP2 infusion was performed under pancreatic clamp conditions to 
determine the ability of aP2 to directly influence Nampt gene expression. 
 
Statistical analysis 
Unless otherwise described, statistical significance testing was performed using 
Student’s t-test; *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± 
SEM for each group. 
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BACKGROUND 
Extended lifespan in rodents subjected to dietary restriction was first 
observed nearly eighty years ago (McCay et al., 1935). Since this discovery, efforts 
have focused on characterization of the physiological parameters that are altered 
under this regimen, identification of genes required for the metabolic shift that 
occurs during caloric restriction, and their subsequent mechanistic role. To date, 
dietary restriction has proven to be the most reproducible way to increase lifespan 
in animals, and it is speculated that the major factor regulating longevity in these 
animals is the diminution of white adipose tissue, perhaps through changes in 
secretion of adipose specific hormones that have peripheral effects on systemic 
metabolism. 
A key defining feature of FABP deficiency is reduced adiposity. Barzilai et al. 
have demonstrated reversal of hepatic insulin resistance and aging in rodents 
under dietary restriction and suggest that a reduction in visceral adipose is the 
chief underlying determinant. Additionally, C.elegans FABPs have been identified in 
RNAi based genetic screens performed by two separate groups as putative 
longevity related genes (Ha et al., 2006).  First by proteomic analysis of genes 
involved in cellular senescence (Ha et al., 2006) and secondly, in a screen 
performed in lipid deficient C. elegans, the worm homologue of aP2 was identified 
among 16 other potential candidate genes that affect fat storage and longevity 
(Wang et al., 2008). 
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Our present finding that circulating aP2 directs NAD metabolism in 
hepatocytes along with several previous studies linking NAD metabolism to the 
positive health effects observed in DR (Imai, 2009) further suggest a critical role for 
adipose tissue in regulating healthspan. To explore this potential, we aimed to 
determine if the lack of lipid chaperone action in adipose tissue mimics DR induced 
modifications in lipid pools, gene regulatory networks, peripheral tissue function 
and long-term survival.  
 
RESULTS 
Adipose tissue alterations in FABP deficiency and dietary restriction 
Our lab has shown that mutations in adipose tissue fatty acid binding proteins aP2 
and mal1 leads to increased production and secretion of a newly identified lipid 
hormone, palmitoleate.  This fatty acid was demonstrated to link peripheral tissues 
in an endocrine network and exert positive effects on metabolic homeostasis. 
Furthermore, palmitoleate is a robust marker of de novo lipogenesis. Interestingly, 
the FABP-mediated changes in adipose tissue lipid composition, and the marked 
increase in de novo lipogenesis preceding this effect, are both highly reminiscent of 
dietary restriction induced adaptations in adipose tissue (Varady et al., 2007).  
Through comparative analysis of individual lipid classes and fatty acid species, we 
identified lipids that are present at similar levels in adipose tissue of DR and FABP-
deficient mice.  We found that FABP deficiency and dietary restriction both led to 
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similar degrees of elevation in fatty acid content in the free fatty acid and 
diacylglycerol lipid fractions (Figures 3-1A and B).  Higher levels of diacylglycerol 
are correlated with lowering of plasma TGs, increased energy expenditure, and 
reduced adiposity (Murase et.al. 2001), and increased adipose tissue free fatty acids 
generated by de novo lipogenesis have proven to be beneficial as a means to 
produce palmitoleate (Cao et.al. 2008).  When comparing changes that occur in 
both FABP deficiency and dietary restriction, palmitoleate levels were increased by 
approximately 65-80% in three major lipid classes (Figure 3-1C). 
After verification that critical constituents of the lipid environment were 
regulated in the same manner by both FABP deficiency and dietary restriction, we 
further queried the molecular underpinnings of this phenotype by contrasting the 
transcriptional profiles of adipose tissue from animals subjected to each of these 
interventions with their respective controls. Compared to ad libitum fed control 
mice, animals on a long-term restricted diet had several hundred genes related 
mainly to carbohydrate and lipid metabolism that were significantly altered in 
adipose tissue. We then derived a comparison between gene expression profiles of 
DR mice and the transcriptional alterations that occurred in aP2-mal1 deficient 
mice when compared with their wild type controls. We determined that the 
regulatory overlap included 57 genes (Figure 3-2). This set included genes 
encoding factors related to amino acid, carbohydrate, lipid and mitochondrial  
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Figure 3-1.  Trends in adipose tissue lipid profiles between adult male aP2-
mal1-/- and dietary restricted mice.  
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Figure 3-1 (Continued).  Trends in adipose tissue lipid profiles between adult 
male aP2-mal1-/- and dietary restricted mice. (A) Fatty acid content (nmol/g) in 
free fatty acid and diacylglycerol lipid pools and (B) palmitoleate levels in adipose 
tissue of aP2-mal1-/- vs. wild type mice and dietary restricted vs. ad libitum fed mice. 
One-way ANOVA and Bonferroni’s multiple comparison test was used to determine 
significance and illustrate trends within each major lipid class (C). Percent increase 
in quantitative levels of palmitoleate in each lipid class was between 65-82% in 
each lipid class.  
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Figure 3-2.  Comparison of gene expression profiles in adipose tissue of aP2-
mal1-/- vs. wild type mice and dietary restricted vs. ad libitum fed mice. 
Common transcriptional responses were determined using in house data obtained 
from FABP-deficient mice generated in our laboratory and publicly available 
microarray data from dietary-restricted mice (NCBI GEO datasets GSE 11845). 
Yellow box indicates 57 genes that are similarly altered by both FABP deficiency 
and dietary restriction. 
aP2-mal1-/- dietary restricted 
wild type ad libitum 
vs. vs. 
•  amino acid 
metabolism 
•  lipid metabolism 
•  carbohydrate 
metabolism 
•  mitochondiral 
energy metabolism 
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energy metabolism; establishing that the phenotypic correlations between these 
interventions extend beyond qualitative changes in lipid content, towards deeper 
molecular parallels, as demonstrated by highly comparable gene expression of key 
metabolic genes such as GLUT4, glycerol-3-phosphate dehydrogenase, fatty acid 
synthase, ATP-citrate lyase, and several mitochondrial enzymes.  
These observations implicated a role for adipose tissue fatty acid binding 
proteins in replicating the improved metabolic outcomes displayed during DR, 
possibly serving as an integrative link between the metabolic outcomes and 
increased survival that result from a DR regimen. Taken together, this cadre of 
physiologal correlates, parallels in adipose tissue lipid environment, and overlap in 
transcriptional regulation between FABP knockouts and mice subjected to the 
lifespan extending DR intervention provided a suitable rationale for conducting a 
long-term survival study in aP2-mal1-/- mice. 
 
Long-term survival 
We endeavored to determine if the lack of FABP action in adipose tissue 
mimicked the pro-health and pro-longevity benefits of dietary restriction.  For this, 
we generated littermate cohorts of 40 wild type and 40 FABP-deficient mice of 
each gender (160 total) and allowed them to live out their normal lifespan. 
Surprisingly, there was a remarkable closeness in survival curves of female wild 
type and aP2-mal1-/- mice, and no degree of statistical difference in either gender. 
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Figure 3-3.  Comparison of survival curves for aP2-mal1-/- vs. wild type mice. 
Kaplan-Meier curve indicates percent survival for males (A)  and females (B) over a 
period of  ~1000 days. N = 40 for each group. 
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Median survival was 739 and 685 days for wild type and aP2-mal1-/- males, 
respectively, while female median life spans were 685 and 703 days, respectively 
(Figure 3-3A and B). 
 
Metabolic fitness in aged mice 
Serum lipids are commonly used as indicators of metabolic health. Male FABP 
deficient animals exhibited numerically higher levels of serum triglycerides, a 
phenotype that was previously reported in young FABP deficient mice (Cao et al, 
2008), yet, this increase did not reach statistical significance for either males or 
females. Additionally, HDL and VLDL levels were similar between genotypes, in both 
males and females. LDL content was not determined in two groups (wild type males or 
FABP deficient females); therefore we were unable to define any similarities or 
differences for this lipoprotein fraction (Figure 3-4A). Such a profile is seemingly 
unreflective of an improved metabolic condition, however, we find that FABP 
deficiency evokes significant qualitative differences in fatty acid species within each 
lipid class. As such, we previously identified significant elevations in palmitoleate in 
adult males, which has the potential to mediate specific metabolic effects on liver and 
muscle to provide major health benefits (Cao et al., 2008). 
Prevention of obesity and reduced body weight is another chief indicator of 
metabolic fitness. Both male and female aP2-mal1-/- mice maintained lower body 
weights at one year of age compared to their wild type counterparts (Figure 3-4B). 
Using dual-energy x-ray absorptiometry, we further confirmed that the observed  
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Figure 3-4.  Serum lipids and body composition. (A) Circulating levels of 
cholesterol, TG, HDL, LDL and VLDL. In serum collected after a 6hour daytime food 
withdrawal (B) Body weight and (C) Body weight composition (lean vs. fat mass). N 
= 4 for each group. ND = not determined (*) = single animal. 
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weight reduction was consistent with reduced adiposity and not the loss of lean tissue 
mass due to muscle wasting (Figure 3-4C).  
 
White adipose tissue 
 Mounting evidence supports a crucial role for obesity-associated inflammation 
in the development of insulin resistance and type 2 diabetes (Hotamisligil 2006). 
Infiltration and activation of adipose tissue macrophages in the obese state produces 
elevated levels of inflammatory cytokines, which stress the homeostatic mechanisms 
that maintain glucose levels. We found aP2-mal1-/- deficient adipose tissue in aged 
males and females to be almost completely void of this characteristic  
macrophage infiltration (Figure 3-4A,B) and females were profoundly resistant to the 
presence of inflammatory cytokines (TNFα, IL-6, and IL-10) in circulation (Figure 3-4B).  
 
Liver 
FABP deficient animals preserved normal liver appearance, contrasted with 
signs of steatosis in wild type livers (Figure 3-6A). While neither genotype exhibited 
particularly high levels of alanine aminotransferase (ALT) in serum, aP2-mal1-/- mice 
had slightly lower levels than wild type (Figure 3-6B). Hepatic lipid accumulation and 
elevated ALT levels are routinely used as tools to assess the degree of liver disease. 
Lack of prominence for either of these elements in aP2-mal1-/- mice marks a trend that 
correlates with a healthier liver.  
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Figure 3-5.  White adipose tissue. Hematoxylin and eosin staining of white 
adipose tissue (representative images from two animals), and circulating levels of 
inflammatory cytokines in (A) males and (B) females.  Cytokine levels in aged mice 
are compared to levels in young adults.  
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Figure 3-6.  Liver tissue.  (A) Hematoxylin and eosin staining of liver sections. (B) 
serum alanine aminotransferase levels.  
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Glucose homeostasis 
Previous data indicated higher glucose tolerance and insulin sensitivity in 
young adult FABP deficient mice compared to their wild type controls (Maeda et al., 
2005). While wild type mice became glucose intolerant and insulin resistant with age, 
these same parameters were unaffected in FABP deficient animals, in fact the curves 
are almost identical to published results for young aP2-mal1-/- mice (Figure 3-7A and B) 
(Maeda et al., 2005). The loss of adiponectin expression is known to promote the 
development of insulin resistance and glucose intolerance (K. Brochu-Gaudreau et al., 
2010). These molecular correlates follow data obtained in female mice, where mean 
adiponectin levels were 43.4 μg/mL compared to 29.9 μg/mL in wild types (Figure 3-
7D).  Paradoxically, aged male aP2-mal1-/- mice have considerably less serum 
adiponectin than their wild type counterparts, a peculiarity also observed in young 
adult aP2-mal1-/- mice (Maeda et al., 2005).  Leptin resistance, marked by a 
compensatory elevation in serum leptin and de-regulated insulin responsiveness (Flier 
J. 1997) is particularly clear in aged wild type animals. Serum leptin levels in wild type 
males and females were 22.9 pg/mL and 25.9 pg/mL, respectively, whereas FABP 
deficiency permitted the maintenance of normal leptin levels (males, 5.6 pg/mL and 
females, 3.0 pg/mL) mice (Figure 3-7E). Since the basis for improved insulin sensitivity 
and glucose tolerance does not depend solely on the action of adipose tissue 
hormones, we also examined pancreas and related hormonal signals. Pancreas 
morphology, as illustrated by immunostaining of islets, was comparable between the 
two genotypes and genders (Figure 3-8A). Relative intensities for β-cell insulin and α-  
Chapter 3 Role for FABPs in healthspan and longevity       
 
	   87 
  
Figure 3-7.  Glucose Homeostasis.	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Figure 3-7 (Continued).  Glucose Homeostasis. (A) Glucose tolerance, (B) insulin 
tolerance, and serum (C) glucose, (D) adiponectin and (E) leptin levels.  Adiponectin 
and leptin levels in aged mice were compared with measurements in young adults 
(4 months old). 
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Figure 3-8.  Pancreatic islets*.  (A) Immunohistochemical staining of glucagon 
producing β-cells (red) and insulin producing α-cells (green) (yellow = merge). (B) 
Quantitation of insulin and glucagon fluorescence. (C) Average islet size.  
*Combined values for males and females. 
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cell glucagon were similar across both genders; therefore these values were 
combined in order to increase statistical power. Relative fluorescent intensities for 
insulin were higher in FABP deficient mice compared to wild type, indicating that 
these animals maintain the functional capacity for insulin production. 
 
Physical appearance in aged mice 
The dietary restriction field has contributed to a growing body of evidence, 
which validates the DR intervention as one that actively slows the aging process 
with respect to organ function, as well as physical appearance (Stern et al., 2001).  
Thus, in addition to demonstrating the effects of FABP-deficiency on healthspan, 
we documented the outward phenotype of these animals to determine if these 
mice also exhibit a delay in visible signs of aging. Both male and female aP2-mal1-/- 
mice retained a more youthful look. While wild type mice were mangy in 
appearance, FABP deficient animals retained more of their original coat color and 
maintained a full coat with intact vibrissae (Figure 3-9). 
 
Metabolic challenge in aged mice 
Though we did not reveal any lifespan extending effects of FABP deficiency in our 
long-term survival study, this determination was made in a cohort of normal fed 
mice. Hence, it remained a possibility that this genetic intervention possessed 
limited power to impact survival in normal aging, distinct from the ability to 
prevent early mortality associated with long-term overnutrition. Therefore, we 
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challenged a cohort of 40 animals (10 male, 10 female, aP2-mal1-/-, 10 male, 10 
female, wild type) with high fat diet (HFD). This regimen is known to provoke 
metabolic stress and further exacerbate insulin resistance. As such, wild type males 
and females increased blood glucose levels by 75 mg/dL and 101 mg/dL, 
respectively (Figure 3-10A). In striking contrast, we found that aged aP2-mal1-/- 
blood glucose levels were virtually unaffected by exposure to HFD, with blood 
glucose level changing by less than 10 mg/dL in both genders (Figure 3-10A). 
Surprisingly though, we again detected no difference in survival, despite a 
profound resistance to one of the major deleterious effects of HFD (Figure 3-10B).  
Interestingly females of both genotypes were less susceptible to HFD-induced 
mortality. Mean survival was > 24 months in females, whereas median survival was 
around 22.6 months in males (Figure 3-10B).  
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Figure 3-9.  Physical appearance of aged mice. Representative photographs of 
1-year-old (A) wild type male (B) aP2-mal1-/- male (C) wild type female (D) aP2-mal1-
/- female mice. 
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Figure 3-10.  Serum glucose and survival after high-fat diet (HFD). At 15 
months of age, mice were placed on HFD chow and continued on this diet for 8 
months. (A) Blood glucose in males and females after 6hour daytime food 
withdrawal. (B) Survival after initiation of HFD WT male = 40%; aP2-mal1-/- male = 
30%; WT female = 60%; aP2-mal1-/- female = 60%. 
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DISCUSSION 
Steadily, obesity has become more apparent in younger age groups, 
predisposing them to an early decline in peripheral tissue function, and 
development of obesity related comorbidities. Perhaps most alarming is that this 
disproportion may eventually manifest in early mortality for a high number of 
overweight and obese individuals. 
Dietary and genetic methods of increased longevity are known to elicit 
changes in gene expression that correlate with lower plasma glucose and insulin 
levels, increased insulin sensitivity, and decreased gluconeogenesis. Given that 
FABP-deficient mice have been shown to exhibit several of the same health 
improvements displayed by rodents on restricted diets, we projected that our mice 
would show signs of increased survival compared to their wild-type counterparts. 
However, we observed an absence of survival enhancement in FABP deficiency, 
indicating that the responsible regulatory pathways involved in increasing lifespan 
are not exclusive to pathways related to improved glucose metabolism and insulin 
signaling. Identification of common metabolic and transcriptional responses 
among interventions that increase life span is fundamental to the discovery of 
genes, metabolites, and pathways underlying mechanisms of aging and for the 
detection of possible age-related biomarkers. However, despite numerous studies 
recounting the health benefits of dietary restriction in several species, such a 
paradigm has provided limited power to detect a mechanism for these effects. In 
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order to move beyond descriptive phenotypes, evaluation of shared transcriptional 
and metabolic responses under regimens that enact the same health benefits 
contributing to longevity could be useful but should be done in parallel with 
analysis of non-overlapping responses.  In light of our results indicating an absence 
of lifespan extension in FABP deficiency, we thought it would be equally useful to 
identify transcriptional responses that were unique to the life extending DR model 
and fail to overlap with phenotypically similar, normal-lived aP2-mal1-/- mice (Table 
3-1). In our transcriptional analysis, genes that follow this criterion are secreted 
peptides, glycoproteins, and proteins involved in redox reactions.  This list may 
contain potential gene families that uphold lifespan extension in a manner that is 
independent of metabolism and more directly impacts chronological lifespan. 
Another quite plausible explanation for lack of lifespan extension is that 
FABP deficiency promotes deterioration of biological function in a specific pathway 
or tissue that counteracts the pro-longevity benefit of metabolic fitness. We have 
no evidence that this is the case for any tissue examined thus far, yet it remains to 
be thoroughly addressed. In mice, common causes of death are cancer and kidney 
failure. In our study, gross pathological examination by two separate scientists 
confirmed that wild type and aP2-mal1-/- mice displayed equal incidences of 
lymphoma in kidney, liver and spleen, and a comparable degree of 
glomerulonephritis (data not shown).  These findings are also in line with mouse 
studies using the sirtuin activator—resveratrol, and reports from dietary restriction 
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studies in primates, where researchers observed robust beneficial health effects 
and survival that was unchanged from their respective controls (Pearson et al., 
2008; Mattison et al., 2012). 
 
 
Table 3-1. Official gene symbols for significantly altered genes with opposing 
directionality in aP2-mal1-/- and DR mice 
 
 
 
While this study indicates that FABPs are perhaps not involved in the 
adipose tissue response to dietary restriction with respect to increasing lifespan, it 
does support an underlying role for FABPs in the aging process, with respect to 
metabolic deterioration. Our study revealed similarities in DR and FABP deficient 
adipose tissue through a comparative analysis of gene expression and lipid profiles 
from DR and FABP deficient mice. We discovered a unique overlap in changes to 
lipid profiles and transcriptional responses when compared to their respective 
Offi ial gene symbols for sig ificantly altered genes with opposing directionality
!AM-/- "DR
Cidea Cldn2 Bex2 1700086L19Rik Spz1
Cox8b Lcn2 Spink12 Cldn4 Tsga2
Ear1 Slc38a5 Defb15 Tuft1 Znrf4
Chgb Cyb561 Rpl3l Calml3 1700016H13Rik
Cd79a Rbm11 5830403L16Rik BC025076 5430433G21Rik
Ccl5 Indo Lcn8 Xkrx Rhcg
Mmp12 Clu Cst12 Tmem46
A130092J06Rik D730048I06Rik Lcn12 Defb13
Orm2 Cryba4 Lcn5 Actg2
Aard Spink2 Ntsr1 Acox3
Sult1a1 Hoxb6 4930525K10Rik Aass
Ubd Slc7a5 Ubqln3 Tnp2
Hist1h4j Defb35 4931407G18Rik Tpd52l1
"AM-/- !DR
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controls. However, the origin of these molecular links remains to be elucidated. 
Our comprehensive histological and biochemical examination of metabolic tissues 
in aged FABP deficient mice illustrated the maintenance of adipose, liver and 
pancreatic function, and provided further evidence that adipose tissue is a major 
regulator of the physiological parameters that connect biological outcomes to 
increased healthspan. Furthermore, this work suggests that the preservation of 
insulin action and glucose homeostasis alone is not sufficient to extend chronological 
lifespan, however, it has a significant impact on healthspan. The lack of an identifiable 
role for FABPs in mouse survival when fed regular diet or after HFD challenge, 
despite the metabolic similarities with DR, suggests that pathways unrelated to 
metabolism are involved in the regulation chronological lifespan, and that time of 
survival is essentially prone to the effects of metabolism on healthspan.  
 
MATERIALS AND METHODS 
Comparison of adipose tissue transcriptome and lipidome in dietary-restriction and FABP 
deficiency 
 
For our large-scale comprehensive analysis of transcriptional regulation in adipose 
tissue, we used fully annotated and downloadable microarray datasets (Gene 
Expression Omnibus Set 11845) available from a published study performed in DR 
mice (Pearson et al., 2008). This study was performed in male C57BL/6NIA mice fed 
a standard mouse diet ad libitum (AIN-93G), or a restricted diet and sacrificed 
between 18-24 months of age. We used the platform independent software 
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program HDBStat! (Trivedi et al., 2005) to compare differentially expressed genes 
between our existing data set for FABP-deficient mice compared to dietary 
restricted mice in the published data set (ex: DR vs. ad libitum and FABP-/- vs. wild 
type). Raw values were subjected to Z-score transformation to account for 
differences in signal intensities across platforms. Z-scores greater than 1.5 and less 
than -1.5 with a p-value threshold of 0.05 and representation in at least 50% of the 
total arrays were considered significant. These values were generated using the R-
statistical package. Since probsets varied between the published array using an 
Illumina mouseRef-8 v1.1 expression beadchip, and our Affymetrix Mouse Genome 
430 2.0 array, we used Resourcerer online database to cross-reference and link the 
array sources (Tsai et al., 2001). The Database for Annotation, Visualization & 
Integrated Discovery (DAVID) was used to transform the significantly regulated 
genes in each data set into functionally related groups (Dennis et al., 2003; Huang 
et al 2009.)  
A similar comparative analysis was performed using the quantitative lipid 
profiles produced from FABP-deficient vs. WT tissue and dietary restricted vs. ad 
libitum fed tissues. Individual lipid classes from adipose tissue were determined by 
TrueMass Profiling—TrueMass Lipomic Panel (Lipomics Technologies, West 
Sacramento, CA). FABP-deficient vs. WT Lipomics data was previously analyzed and 
reported by Cao et al., 2008 and were utilized in this study for purposes of 
comparison. 
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Longevity Experiments  
 
WT and aP2-mal1-/- littermates were generated from heterozygous breeder pairs. 
Upon weaning, WT and FABP-deficient mice were assigned to a survival cohort and 
allowed to live out their normal lifespan. Survival was measured as the number of 
days from birth recorded until death, and analyzed using Kaplan-Meier survival 
curves. A second cohort of aged mice was used for healthspan studies, gross 
pathology and microscopic analysis of tissues. These experiments were performed 
at the Barshop Institute for Longevity and Aging Studies at the University of Texas 
Health Science Center at San Antonio and the pathology core at Dana Farber 
Cancer Institute in Boston Massachusetts. All pathological scoring was based on 
observations from at least two pathologists.  
 
Glucose and insulin tolerance tests 
Glucose tolerance tests were performed by intra peritoneal injection of glucose at a 
dose of 1.0g/Kg after a 16hour overnight fast. Insulin tolerance tests were 
performed by by intra peritoneal injection of insulin at a dose of 1U/Kg after a 
6hour daytime food withdrawal.  Glucose levels were read using Breeze2 glucose 
test strips. 
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NEW PERSPECTIVES AND CONCLUSION POINTS 
Effects of aP2 inhibition on NAD metabolism may confer stress resistance 
Among the theories for how dietary restriction mediates positive effects on 
aging, is the idea that DR reduces oxidative damage to macromolecules caused by 
reactive oxygen species (ROS) generated during respiration. Since it has been 
demonstrated that the metabolic rate in dietary-restricted animals is not altered 
significantly (McCarter et al., 1985), the reduction in ROS is attributed to an 
enhanced capacity of DR mice to detoxify ROS, as these mice show increased super 
oxide dismutase activity in the liver. Although it has not been demonstrated to be 
the case in mice, over expression of superoxide dismutase alone can extend 
lifespan in Drosophila and yeast (Sun et al., 2004, Harris et al., 2003).  
NADH driven oxidative phosphorylation, although beneficial for the cell in 
terms of ATP production, can become harmful over time. Electrons carried by the 
electron transport chain are routinely transferred to the terminal electron acceptor, 
oxygen, ultimately producing water. However, this relatively benign reaction 
sometimes allows premature electron leakage and the appearance of incompletely 
reduced intermediate forms of molecular oxygen (O2-, H202 and OH) termed 
reactive oxygen species. Damage to lipids, proteins and DNA can occur when these 
species react with and disrupt bonds that form these macromolecules (de 
Magalhaes et al., 2006; Stadtman 2006). Cellular defense mechanisms exist to 
combat the generation of these harmful species, and their damaging effects. For 
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example, superoxide dismutases and catalase detoxify superoxides and peroxides, 
respectively; and thioredoxins can reduce proteins that have been damaged by 
reacting with ROS. Additionally, excess mitochondrial NADH has been shown to 
protect against peroxide induced cell death in a human monocytic cell line (U937). 
By chemically inducing the production of sufficient reducing equivalents to 
neutralize ROS, authors were able to rescue cells from toxicity (Brambilla et al., 
1998). 
We tested this paradigm in primary hepatocytes isolated from wild type and 
aP2-mal1-/- mice by exposure to tert-butylhydroperoxide (tBOOH) and subsequent 
probing with CellROX Deep Red reagent. We began with primary cells that were 
equally viable (Figure 4-1), and with increasing concentrations of tBOOH, control 
hepatocytes exhibited intense fluorescent signal corresponding with an 
accumulation of ROS (Figure 4-2A). In comparison, FABP cells exhibited low-level 
diffuse CellROX staining, even at the highest concentration of peroxide, consistent 
with a markedly reduced presence of ROS (Figure 4-2A). To probe whether or not 
the inhibition of ROS generation was protective against DNA damage, this same 
experimental paradigm was used. For this, we employed single cell gel 
electrophoresis of oxidant exposed primary hepatocytes and subsequent staining 
with SYBR green to detect strand breaks. Three-dimensional surface plots illustrate 
“comets” that are representative of those generated under the highest 
concentration of tBOOH (Figure 4-2B). Higher concentrations of tBOOH (4.8mM) 
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were required to induce DNA damage than that which induced ROS (2.4mM). 
Despite this, wild type hepatocytes were still more sensitive to oxidant exposure 
and produced comet tails of greater length and higher density, corresponding to a 
modest increase in levels of DNA damage, compared to aP2-mal1-/- cells (Figure 4-
2C-D). It is possible that the decreased presence of tBOOH induced DNA damage in 
hepatocytes was related to the elevated expression of liver PARP (as demonstrated 
in Figure 2-3A and 2-3B).   Taken together, these data support an antioxidant role 
for surplus NADH and designates fatty acid binding proteins as molecules that can 
potentially counteract the restorative nature of liver. 
In this setting, we can follow-up this finding by determining if NAD 
metabolism is altered in other peripheral tissues, if additional cell types exhibit 
cytoprotection, and/or whether these cell types are protected against additional 
physiological stressors. Correlating these outcomes with FABP-deficiency will 
strengthen our hypotheses regarding the role of aP2 in counteracting the 
recuperative ability of metabolic tissues. 
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Figure 4-1.  Cell Viability of primary hepatocytes after isolation 
(A) DAPI; nuclei (B) ethidium homodimer-1; dead cells (C) calcein-AM; live cells (D) 
overlay of A-C. 
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Figure 4-2.  Cytoprotection in aP2-mal1-/- primary hepatocytes. 
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Figure 4-2 (Continued).  Cytoprotection in aP2-mal1-/- primary hepatocytes. 
 (A) Protection from ROS species generation. Primary hepatocytes were incubated for 
30min with indicated concentrations of tBOOH. ROS species detected with CellROX 
Deep Red reagent (B-C) Comet tail length (B) and density (C). Primary hepatocytes 
were exposed to tBOOH as in panel A. Quantitation of comet properties, including 
average tail length and tail density were determined using Image J. (E). Surface 
Plots. Representative 3-D surface plots of SYBR green fluorescent images. Top 
panels, no treatment (NT) bottom panels, 4.8mM tBOOH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: New Perspectives and Conclusion points       
 
	   112 
aP2 as a potential therapeutic target and biomarker for metabolic aging 
Chapter 2 describes a role for aP2 in directing substrate utilization and NAD 
metabolism in hepatocytes (Figure 4-3). The implications of these effects are far 
reaching, given that NAD is central to many fundamental metabolic processes. The 
energy stored in reduced NAD supplies metabolic flux in all living cells, without 
which, many biochemical reactions would be rendered useless. Regulation of NAD 
metabolism is critical for processes that convert nutritional energy to cellular 
energy. Thus, the modulation of NAD levels by targeting aP2 carries with it, the 
potential to reprogram these metabolic events. Furthermore, alterations in adipose 
tissue lipidomic and transcriptional profiles identified in Chapter 3 can potentially 
have profound effects on levels of secreted factors present in serum, which 
contribute to systemic metabolism and extension of healthspan.  
Criteria for biomarkers of aging set by Redman (Redman et al., 2008) put 
forth that the proposed factor must reflect physiological or functional age as 
demonstrated by temporal changes in baseline levels of a given factor, such as an 
expressed gene or molecule. Biological response to this factor must be slowed or 
reversed by caloric restriction and perhaps most crucial, the marker must be 
reliably measured. To date, the most reliable measures in mammals that meet 
these criteria are circulating levels of hormones (i.e. insulin, IGF) (Redman et al., 
2008). Although FABP-deficient mice have significantly lower circulating levels of 
insulin compared to normal mice when both are placed on a high-fat diet, on  
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Figure 4-3.  Regulatory model for adipose tissue fatty acid binding protein 4 
(aP2). Role for aP2 in directing substrate usage through the regulation of NAD, 
glucose and fatty acid metabolism. 
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regular diet, insulin levels are comparable, at least as determined up to 9-months 
of age (Maeda et al., 2005).  Therefore, in some settings, insulin does not serve as a 
reliable biomarker for metabolic aging.  Though it is known that serum aP2 levels 
increase with adiposity, and that adiposity increases with age, it would be useful to  
measure serum levels of aP2 in wild type animals over time in order to determine if 
there are temporal changes that occur during the aging process. If so, aP2 may be 
employed as a biomarker that is consistent with biological aging. 
Though we have now identified several protective features of FABP 
deficiency in the context of obesity and aging, it is important to thoroughly 
evaluate the effects of this intervention on adipocyte health and whole body organ 
function.  Much like the design of simple machines such as levers or pulleys, drug 
therapies make synthetic connections between the existing input and the desired 
outcome; and like simple machines, potential therapeutics must be evaluated for 
their efficiency. It is important to identify a possible trade-off when reprogramming 
metabolism through inhibition of aP2. And if so, is the trade-off significant? 
Though this study did not identify any deleterious effects of acute or long-term 
adipose tissue FABP deficiency, there are many functional aspects of this protein 
that remain unknown. This current work advances our understanding of aP2 
mediated metabolic functions, however, more work is also necessary to further our 
understanding of factors that alter the functional characteristics of aP2. Several 
potential sites for modification exist within adipose tissue, circulation, and in the  
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periphery, where aP2 may encounter post-translational modifications or specific 
lipid ligands. Nevertheless, our studies support the possibility for pharmacologic 
manipulation of FABPs as a potential approach to combat the effects of metabolic 
disease and aging.  
 
MATERIALS AND METHODS 
Reactive oxygen species and DNA damage detection 
Primary hepatocytes were seeded onto glass coverslips and allowed to recover for 
24h after isolation. Cells were washed once with PBS and incubated with indicated 
concentrations of tert-butylhydroperoxide for 30 min at 370C, 5% CO2. The cells 
were washed once with PBS allowed to recover from oxidant exposure for 4h in 
DMEM containing 10% calf serum and used immediately for detection of reactive 
oxygen species or DNA damage. For ROS detection, cells were incubated with Cell 
ROX deep red reagent at a dilution of 1:500 (Invitrogen #C10422) for 30 minutes, 
washed once with PBS and fixed for 15min using 3.7% formaldehyde solution. 
Fluorescence was measured using the far-red filter on a Leica microscope. To 
detect DNA damage, a CometAssay reagent kit (Trevigen # 4250-050-K) was used. 
Cell pellets were collected into the provided alkaline buffer and electrophoresed 
under alkaline conditions for the detection of both single stranded and double 
stranded breaks. Image J was used for quantitation of comet tail length and 
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density, N >50 for each condition. Cell viability after each isolation was determined 
using the LiveDead Assay (Invitrogen). 
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